Deep brain stimulation
DBS was approved in the United States by the Food and Drug Administration for the treatment of Parkinson's in 2002. DBS carries the risks of major surgery, with a complication rate related to the experience of the surgical team.  The major complications include hemorrhage (1–2%) and infection (3–5%).